{"doi":"10.1111/ijpo.13154","title":"An open‐label 16‐week study of liraglutide in adolescents with obesity post‐sleeve gastrectomy","abstract":"BACKGROUND: Up to 50% of adolescents who undergo metabolic and bariatric surgery (MBS) have obesity 3 years post-MBS, placing them at continued risk for the consequences of obesity. OBJECTIVES: We conducted an open-label, 16-week pilot study of liraglutide in adolescents with obesity after sleeve gastrectomy (SG) to investigate liraglutide effects on weight and body mass index (BMI) post-SG. METHODS: Adolescents aged 12-20.99 years with obesity and a history of SG ≥1 year prior were enrolled. Liraglutide was initiated at 0.6 mg/day, escalated weekly to a maximum of 3 mg/day, with treatment duration 16 weeks. Fasting laboratory assessments and an oral glucose tolerance test were performed at baseline and end-treatment. RESULTS: ), and 31 (91%) attended the end-treatment visit. BMI decreased by 4.3% (p < 0.001) with liraglutide. Adolescents who had poor initial response to SG (<20% BMI reduction at BMI nadir) had less weight loss with liraglutide. Fasting glucose and haemoglobin A1C concentrations significantly decreased. There were no serious treatment-emergent adverse events reported. CONCLUSIONS: Liraglutide treatment was feasible and associated with a BMI reduction of 4.3% in adolescents who had previously undergone SG, quantitatively similar to results obtained in adolescents with obesity who have not undergone MBS.","journal":"Pediatric Obesity","year":2024,"id":468779,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":3,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9054,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1140312,"name":"Ejike E. Nwosu","orcid":null,"position":1,"is_corresponding":false},{"id":937756,"name":"Syeda Fatima","orcid":"0000-0003-1425-7707","position":2,"is_corresponding":false},{"id":434577,"name":"Evan P. Nadler","orcid":"0000-0001-8312-4647","position":3,"is_corresponding":false},{"id":1301810,"name":"Nazrat Mirza","orcid":"0000-0002-4163-7310","position":4,"is_corresponding":false},{"id":402284,"name":"Sheila M. Brady","orcid":"0000-0002-2333-3575","position":5,"is_corresponding":false},{"id":1103797,"name":"Sara Turner","orcid":null,"position":6,"is_corresponding":false},{"id":272693,"name":"Shanna Yang","orcid":null,"position":7,"is_corresponding":false},{"id":1076448,"name":"Julia Lazareva","orcid":null,"position":8,"is_corresponding":false},{"id":1302259,"name":"Jennifer A. Te‐Vasquez","orcid":null,"position":9,"is_corresponding":false},{"id":231172,"name":"Kong Y. Chen","orcid":"0000-0002-0306-1904","position":10,"is_corresponding":false},{"id":270254,"name":"Stephanie T. Chung","orcid":"0000-0001-6989-0417","position":11,"is_corresponding":false},{"id":402285,"name":"Jack A. Yanovski","orcid":"0000-0001-8542-1637","position":12,"is_corresponding":false},{"id":434576,"name":"Anna Zenno","orcid":"0000-0001-7502-6422","position":0,"is_corresponding":true}],"reference_count":36,"raw_metadata":null,"created_at":"2026-07-19T02:05:23.500722Z","pmid":"39103247","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}